Inactive Instrument

Spark Therapeutics, Inc.

US84652J1034

Biotechnology & Medical Research

Spark Therapeutics Appoints Michael Retterath as Chief Strategy Officer

November 16, 2020 at 07:30 am EST

Spark Therapeutics announced the appointment of Michael Retterath as chief strategy officer. Michael joins Spark Therapeutics from Bain & Company.

Latest news about Spark Therapeutics, Inc.

Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	23-10-14	CI
Spark Therapeutics, Inc. Enters into Strategic Collaboration with Neurochase Limited for Use of Proprietary Delivery Technology for CNS Disorders	23-01-27	CI
Spark Therapeutics, Inc. Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A	22-12-12	CI
Spark Therapeutics, Inc. Announces Executive Changes, Effective April 1, 2022	22-02-23	CI
Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	21-12-16	CI
Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII Expression that Significantly Reduced Bleeding in Hemophilia A Patients	21-11-17	CI
CombiGene in Billion-Dollar Deal with Spark Therapeutics	21-10-12	CI
NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease	21-09-07	CI
Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date	21-07-21	CI
Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform	21-04-13	CI
Spark Therapeutics Appoints Cynthia Pussinen as Chief Technical Officer	21-02-25	CI
Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress	21-02-05	CI
Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease	21-02-01	CI
Spark Therapeutics Appoints Michael Retterath as Chief Strategy Officer	20-11-16	CI
Spark Therapeutics, Inc. Appoints Gallia Levy as Chief Medical Officer	20-08-10	CI
Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress	20-07-12	CI
Spark Therapeutics, Inc. Demonstrates Role of Ides in Enabling of Gene Therapy in the Presence of Neutralizing Anti-Aav Antibodies Published in Nature Medicine	20-06-01	CI
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from S&P TMI Index	19-12-23	CI
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from S&P Global BMI Index	19-12-23	CI
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from S&P Biotechnology Select Industry Index	19-12-23	CI
Trouble for Boeing, Netflix expands, Amazon toughens up against Fedex…	19-12-17
Spark Therapeutics, Inc. Announces Board Changes	19-12-17	CI
Spark Therapeutics : Roche to complete $4.3 billion Spark deal as regulators give all clear	19-12-17	RE
Spark Therapeutics : Roche to complete $4.3 billion Spark deal as regulators give all clear	19-12-17	RE
Spark Therapeutics, Inc.(NasdaqGM:ONCE) dropped from NASDAQ Composite Index	19-12-17	CI

Chart Spark Therapeutics, Inc.

Duration

Period

More charts

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

Spark Therapeutics, Inc.

Equities

US84652J1034

Biotechnology & Medical Research

Spark Therapeutics Appoints Michael Retterath as Chief Strategy Officer

Latest news about Spark Therapeutics, Inc.

Chart Spark Therapeutics, Inc.

Company Profile

Sector Bio Therapeutic Drugs